Characteristics |
Normal PR interval (N=5716) |
Normal PR interval (N=5716) |
|
Prolonged PR interval
(N=472) |
Prolonged PR interval (N=472) |
Prolonged PR
interval (N=472) |
P-value |
|
QRS axis >37° |
QRS axis ≤37° |
|
QRS axis
>37° |
QRS axis >37° |
QRS axis ≤37° |
|
|
(N=2891) |
(N=2825) |
|
(N=183) |
(N=183) |
(N=289) |
|
Age, yrs |
55.1±12.2 |
60.0±13.1 |
|
60.1±13.1 |
60.1±13.1 |
67.8±13.3 |
<0.001 |
Female sex, % |
1672 (57.8) |
1534 (54.3) |
|
79 (43.2) |
79 (43.2) |
119 (41.2) |
<0.001 |
White, % |
2104 (72.8) |
2046 (72.4) |
|
113 (61.7) |
113 (61.7) |
201
(69.6) |
0.009 |
Total annual income <$20K, % |
1181 (41.5) |
1345 (48.5) |
|
74 (40.9) |
74 (40.9) |
139 (49.6) |
<0.001 |
Current smoke, % |
797 (27.6) |
511 (18.1) |
|
55 (30.1) |
55 (30.1) |
40 (13.8) |
<0.001 |
Body mass index, kg/m2
|
26.6±5.4 |
28.5±5.4 |
|
27.1±5.7 |
27.1±5.7 |
29.1±5.8 |
<0.001 |
Diabetes mellitus, % |
214 (7.4) |
353 (12.5) |
|
16 (8.7) |
16 (8.7) |
35 (12.1) |
<0.001 |
History of CVD†, % |
384 (13.5) |
297 (10.7) |
|
21 (11.6) |
21 (11.6) |
28 (10.0) |
0.007 |
Antihypertensive medications use, % |
539 (18.8) |
888 (31.5) |
|
67
(36.6) |
67 (36.6) |
131 (45.6) |
<0.001 |
Cancer, % |
247 (8.5) |
283 (10.0) |
|
18 (9.8) |
18 (9.8) |
53 (18.3) |
<0.001 |
AV nodal drug use‡, % |
134 (4.6) |
186 (6.6) |
|
21 (11.5) |
21 (11.5) |
36 (12.5) |
<0.001 |
HDL-c§, mg/dL |
52.7±16.5 |
50.6±16.2 |
|
51.7±17.9 |
51.7±17.9 |
49.9±16.1 |
<0.001 |
Diastolic blood pressure, mmHg |
76.8±11.7 |
79.0±12.2 |
|
77.1±13.8 |
77.1±13.8 |
76.3±12.7 |
<0.001 |
Systolic blood pressure, mmHg |
129.2±19.9 |
136.2±20.2 |
|
132.8±20.1 |
132.8±20.1 |
138.4±21.9 |
<0.001 |
Corrected QT interval, ms |
428.7±22.7 |
432.2±23.6 |
|
423.6±25.0 |
423.6±25.0 |
425.7±25.5 |
<0.001 |
Heart rate, bpm |
68.9±11.2 |
68.7±11.5 |
|
65.0±10.0 |
65.0±10.0 |
63.9±11.4 |
<0.001 |
PR interval, ms |
156.4±21.6 |
159.7±20.3 |
|
215.3±14.3 |
215.3±14.3 |
220.0±20.6 |
<0.001 |
QRS duration, ms |
94.6±9.8 |
95.7±9.7 |
|
95.5±10.9 |
95.5±10.9 |
96.1±10.6 |
<0.001 |
P-wave duration, ms |
108.6±12.8 |
111.7±13.5 |
|
123.7±14.4 |
123.7±14.4 |
127.9±15.9 |
<0.001 |
Negative P-wave V1, uV |
-33.0 [-51.0, -18.0] |
-39.0 [-55.0,
-24.0] |
|
-41.0 [-60.0, -27.0] |
-41.0 [-60.0, -27.0] |
-48.0
[-64.0, -33.0] |
<0.001 |
P-wave axis, ° |
67.0 [53.0, 77.0] |
59.0 [44.0, 70.0] |
|
66.0
[48.5, 77.0] |
66.0 [48.5, 77.0] |
55.0 [41.0, 68.0] |
<0.001 |
QRS axis, ° |
60.0 [49.0, 73.0] |
12.0 [-6.0, 25.0] |
|
60.0
[49.5, 72.0] |
60.0 [49.5, 72.0] |
5.0 [-11.0, 22.0] |
<0.001 |
Values are expressed as mean ± SD, N (%) or median values [first
quartile, third quartile]. |
Values are expressed as mean ± SD, N (%)
or median values [first quartile, third quartile]. |
Values are
expressed as mean ± SD, N (%) or median values [first quartile, third
quartile]. |
Values are expressed as mean ± SD, N (%) or median
values [first quartile, third quartile]. |
Values are expressed as
mean ± SD, N (%) or median values [first quartile, third quartile]. |
Values are expressed as mean ± SD, N (%) or median values [first
quartile, third quartile]. |
Values are expressed as mean ± SD, N (%)
or median values [first quartile, third quartile]. |
Values are
expressed as mean ± SD, N (%) or median values [first quartile, third
quartile]. |
†CVD: cardiovascular disease; ‡AV nodal drug use: β-blocker or
Dihydropyridine calcium blocker; §HDL-c: high-density lipoprotein
cholesterol. |
†CVD: cardiovascular disease; ‡AV nodal drug use:
β-blocker or Dihydropyridine calcium blocker; §HDL-c: high-density
lipoprotein cholesterol. |
†CVD: cardiovascular disease; ‡AV nodal drug
use: β-blocker or Dihydropyridine calcium blocker; §HDL-c: high-density
lipoprotein cholesterol. |
†CVD: cardiovascular disease; ‡AV nodal drug
use: β-blocker or Dihydropyridine calcium blocker; §HDL-c: high-density
lipoprotein cholesterol. |
†CVD: cardiovascular disease; ‡AV nodal drug
use: β-blocker or Dihydropyridine calcium blocker; §HDL-c: high-density
lipoprotein cholesterol. |
†CVD: cardiovascular disease; ‡AV nodal drug
use: β-blocker or Dihydropyridine calcium blocker; §HDL-c: high-density
lipoprotein cholesterol. |
†CVD: cardiovascular disease; ‡AV nodal drug
use: β-blocker or Dihydropyridine calcium blocker; §HDL-c: high-density
lipoprotein cholesterol. |
†CVD: cardiovascular disease; ‡AV nodal drug
use: β-blocker or Dihydropyridine calcium blocker; §HDL-c: high-density
lipoprotein cholesterol. |